These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9232612)

  • 21. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial.
    Karthaus M; Rosenthal C; Huebner G; Paul H; Elser C; Hertenstein B; Krauter J; Scharmann T; Geissler RG; Heil G; Ganser A
    Bone Marrow Transplant; 1998 Oct; 22(8):781-5. PubMed ID: 9827976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The optimal use of granulocyte macrophage colony stimulating factor in radiation induced mucositis in head and neck squamous cell carcinoma.
    Patni N; Patni S; Bapna A
    J Cancer Res Ther; 2005; 1(3):136-41. PubMed ID: 17998644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
    Rossi A; Rosati G; Colarusso D; Manzione L
    Oncology; 2003; 64(4):353-60. PubMed ID: 12759532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters.
    Won JH; Ji JE; Ahn KH; Kim SK; Choi JM; Ha HC; Kim HM; Yun CK; Han K; Kim DK
    Biol Pharm Bull; 2013; 36(3):425-31. PubMed ID: 23449328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
    Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
    Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors.
    van Pelt LJ; de Craen AJ; Langeveld NE; Weening RS
    Pediatr Hematol Oncol; 1997; 14(6):539-45. PubMed ID: 9383806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study.
    Makkonen TA; Minn H; Jekunen A; Vilja P; Tuominen J; Joensuu H
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):525-34. PubMed ID: 10701730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia.
    Gözdasoglu S; Unal E; Yavuz G; Pamir A; Reisli I; Deda G; Tarcan A; Babacan E; Cavdar AO
    J Chemother; 1995 Oct; 7(5):467-9. PubMed ID: 8596135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma.
    Kannan V; Bapsy PP; Anantha N; Doval DC; Vaithianathan H; Banumathy G; Reddy KB; Kumaraswamy SV; Shenoy AM
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1005-10. PubMed ID: 9169806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
    Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash.
    Nicolatou-Galitis O; Dardoufas K; Markoulatos P; Sotiropoulou-Lontou A; Kyprianou K; Kolitsi G; Pissakas G; Skarleas C; Kouloulias V; Papanicolaou V; Legakis NJ; Velegraki A
    J Oral Pathol Med; 2001 Sep; 30(8):471-80. PubMed ID: 11545238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
    Stokman MA; Spijkervet FK; Boezen HM; Schouten JP; Roodenburg JL; de Vries EG
    J Dent Res; 2006 Aug; 85(8):690-700. PubMed ID: 16861284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
    Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
    Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
    Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
    Crawford J; Tomita DK; Mazanet R; Glaspy J; Ozer H
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):187-93. PubMed ID: 10850381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.